The FDA approved Pfizer’s transthyretin stabilizer tafamidis, the first treatment for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), a rare, incurable disease. Pfizer will sell the oral drugs under the names Vyndaqel and Vyndamax.
The FDA approved Pfizer’s transthyretin stabilizer tafamidis, the first treatment for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), a rare, incurable disease. Pfizer will sell the oral drug in 2 dosage forms under the names Vyndaqel and Vyndamax. According to Reuters, Pfizer set the list price at $225,000 annually.
ATTR is characterized by the buildup of abnormal deposits of misfolded protein called amyloid in the heart and is defined by restrictive cardiomyopathy and progressive heart failure. The approval was based on data from the pivotal phase 3 Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (ATTR-ACT), the first global, double-blind, randomized, placebo-controlled clinical drug study for this disease. In ATTR-ACT, tafamidis significantly reduced the hierarchical combination of all-cause mortality and frequency of cardiovascular-related hospitalizations compared with placebo over a 30-month period (P = .0006). Additionally, individual components of the primary analysis demonstrated a relative reduction in the risk of all-cause mortality and frequency of cardiovascular-related hospitalization of 30% (P = .026) and 32% (P <.0001), respectively, with tafamidis versus placebo. Approximately 80% of total deaths were cardiovascular-related in both treatment groups.
Tafamidis also had significant and consistent treatment effects compared with placebo on functional capacity and health status first observed at 6 months and continuing through 30 months. Specifically, tafamidis reduced the decline in performance on the 6-minute walk test (P <.0001) and reduced the decline in health status as measured by the Kansas City Cardiomyopathy Questionnaire—Overall Summary score (P <.0001).
Previous options included symptom management, and, in rare cases, heart (or heart and liver) transplant. It is estimated that the prevalence of ATTR-CM is approximately 100,000 people in the United States and only 1% to 2% of those patients are diagnosed.
According to the Amyloidosis Foundation, wild-type ATTR is considered a disease of aging and typically affects men; patients are being diagnosed at a younger age. In some cases, the first symptom is carpal tunnel syndrome as proteins deposit in the wrist; protein involvement may also involve the spine or tendons in the arm. The foundation said that for hereditary ATTR, there are approximately 136 different genetic variations in ATTR, and at least 60 genetic variations in non-TTR hereditary amyloidosis diseases.
The recommended dosage is either Vyndaquel 80 mg orally once daily, taken as four 20-mg capsules, or Vyndamax 61 mg orally once daily, taken as a single capsule. Pfizer said that Vyndamax was developed for patient convenience and that the 2 formulations are not substitutable on a per-milligram basis.
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Contributor: How Patients and Caregivers Can Be a Catalyst for Rare Disease Innovation
November 5th 2023Patient input and experiences play a crucial role in advancing rare disease research and therapy development, as they help define the disease, inform clinical trial design, and influence regulators and payers' decisions, ultimately serving as catalysts for innovation in the field.
Read More